-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

802.P1.24 802. Chemical Biology and Experimental Therapeutics: Poster I

Symposia: Chemical Biology and Experimental Therapeutics Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)

Mithun Sarangdhar, Ph.D.1*, Eric O'Brien, B.Sc.1*, Brett VanCauwenbergh, B.Sc.1*, Mitali Basu, M.Sc.1*, Jonah Snyder1*, Grace Leuenberger1* and John Peter Perentesis, MD2

1CBDI-Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
2Cincinnati Children's Hospital, Cincinnati, OH

Miwako Nishio, PhD1*, Mayumi Yoshimori, PhD2,3*, Kotaro Yoshioka, MD, PhD4*, Yuri Maekawa2*, Rintaro Hara, PhD4*, Takanori Yokota, MD, PhD4*, Ryusuke Nabeshima, PhD5* and Ayako Arai, MD, PhD2,6,7

1Department of Hematology and Biophysical Systems Analysis, Institute of Science Tokyo, Tokyo, Japan
2Department of Hematology and Biophysical Systems Analysis, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
3Center of Blood Transfusion and Cell Therapy, Tokyo Medical and Dental University Hospital (TMDU), Tokyo, Japan
4Department of Neurology and Neurological Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
5Bioresource Management, Drug Discovery Biologics, Ono Pharmaceutical Co., Ltd, Tokyo, Japan
6Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki-Shi, Japan
7Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Chad A. Lewis, PhD1*, Charles Schmidt, PhD2*, Lisa Beebe, PhD3* and Terry Connolly, PhD1*

1K36 Therapeutics, Cambridge, MA
2Reaction Biology, Malvern, PA
3BB Preclinical Consulting, Acton, MA

Min Wu, MD, PhD1, Lingyun Tang, PhD2*, Bo Jiao, PhD3*, Ping Liu, MD, PhD3*, Junmin Li, MD, PhD3* and Ruibao Ren, MD, PhD3

1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, AL, China
2State Key Laboratory of Medical Genomics, Research Center for Experimental Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Mansi Arora, PhD1*, Richard Centore, PhD1*, Mark Charles, PhD2*, Yiwen Chen, PhD1*, Matthew Watson, PhD2*, Magdalena Czekalska, PhD2*, Marius Rebmann, PhD2*, Mahmoud Ghandi, PhD1*, Jerome Cattin, PhD2*, Nagakumar Bharatham, PhD2*, Prathima Radhakrishnan, PhD1*, Alexander Howarth, PhD2*, William E Arter, PhD2*, Seema Qamar, PhD2*, Laura Andraghetti2*, Kadi Saar, PhD2*, Andrew Seeber, PhD1*, Michael G. Kharas, PhD3, Martin Kulander2*, Tuomas Knowles, PhD2,4* and Shilpi Arora, PhD1*

1Transition Bio, Inc, Watertown, MA
2Transition Bio, Ltd, Cambridge, United Kingdom
3Memorial Sloan Kettering Cancer Center, New York, NY
4University of Cambridge, Cambridge, United Kingdom

Mengyao Wang, MD1,2,3*, Qian Hu, PhD2,3,4* and Ting Niu, MD, PhD3,5,6

1Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
2State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China
4Department of Hematology, West China Hospital, Sichuan University, Chengdu, AL, China
5Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
6Department of Hematology, West China Hospital of Sichuan University, Chengdu, China

Hongwon Lee1*, Byungsan Choi, PhD2*, Saem Hong, MS2*, Yunseo Lee, BS2*, Janghee Woo, MD, PhD3 and Tae-Young Yoon, PhD2*

1PROTEINA Co., Ltd., Seoul, South Korea
2PROTEINA Co., Ltd., Seoul, Korea, Republic of (South)
3Winship Cancer Institute of Emory University, Atlanta, GA

Yunda Hong1,2,3*, Dabing Chen3,4,5*, Jingjing Xu3,4,5*, Yanxin Chen, MD, PhD1*, Yangtao Wu6,7*, Yang Shi6,7*, Tianying Zhang6,7*, Quan Yuan6,7*, Ningshao Xia6,7*, Ting Yang3,4,5* and Jianda Hu, PhD1,2,3

1Fujian Medical University Union Hospital, Fuzhou, China
2The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
3Institute of Precision Medicine, Fujian Medical University, Fuzhou, China
4Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
5Department of Hematology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China
6State Key Laboratory of Vaccines for Infectious Diseases,Xiang An Biomedicine Laboratory,Department of Laboratory Medicine, School of Public Health,Xiamen University, Xiamen, China
7National Institute of Diagnostics and Vaccine Development in Infectious Diseases,State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Innovation Platform for Industry-Education Intergration in Vaccine Research,Xiamen University, Xiamen, China

*signifies non-member of ASH